Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citicoline Effect on NAION
NCT03046693Phase 4Completed
- Start
- Jan 2017
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in non-arteritic anterior ischemic optic neuropathy (NAION) comparing Citicoline with Placebo (2 arms). Primary endpoints: P50 wave amplitude at 60 days and N95 wave amplitude at 60 days. Started Jan 2017; status: completed.
02
Drugs
citicoline
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on NCT03046693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03046693.